Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$4.55 -0.09 (-1.94%)
As of 07/3/2026 02:43 PM Eastern
Compare

BCT vs. SCYB, COM, HBP, NVH, and IGX

Should you buy BriaCell Therapeutics stock or one of its competitors? MarketBeat compares BriaCell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BriaCell Therapeutics include Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Helix BioPharma (HBP), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry.

How does BriaCell Therapeutics compare to Scythian Biosciences?

BriaCell Therapeutics (TSE:BCT) and Scythian Biosciences (CVE:SCYB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BriaCell Therapeutics had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for BriaCell Therapeutics and 0 mentions for Scythian Biosciences. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Scythian Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Scythian Biosciences' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Scythian Biosciences N/A N/A N/A

Summary

BriaCell Therapeutics beats Scythian Biosciences on 3 of the 5 factors compared between the two stocks.

How does BriaCell Therapeutics compare to 138267 (COM.TO)?

BriaCell Therapeutics (TSE:BCT) and 138267 (COM.TO) (TSE:COM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BriaCell Therapeutics had 1 more articles in the media than 138267 (COM.TO). MarketBeat recorded 1 mentions for BriaCell Therapeutics and 0 mentions for 138267 (COM.TO). BriaCell Therapeutics' average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
138267 (COM.TO) Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

138267 (COM.TO)'s return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
138267 (COM.TO) N/A N/A N/A

Summary

BriaCell Therapeutics beats 138267 (COM.TO) on 3 of the 5 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.0% of BriaCell Therapeutics shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Comparatively, 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Helix BioPharma's return on equity of -21.54% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
BriaCell Therapeutics N/A -147.92%-122.71%

Helix BioPharma has a beta of 0.421776, indicating that its share price is 58% less volatile than the broader market. Comparatively, BriaCell Therapeutics has a beta of 1.982274, indicating that its share price is 98% more volatile than the broader market.

In the previous week, Helix BioPharma and Helix BioPharma both had 1 articles in the media. Helix BioPharma's average media sentiment score of 1.38 beat BriaCell Therapeutics' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Helix BioPharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BriaCell Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BriaCell Therapeutics beats Helix BioPharma on 6 of the 9 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Novoheart?

BriaCell Therapeutics (TSE:BCT) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Novoheart's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Novoheart N/A N/A N/A

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BriaCell Therapeutics has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

In the previous week, BriaCell Therapeutics had 1 more articles in the media than Novoheart. MarketBeat recorded 1 mentions for BriaCell Therapeutics and 0 mentions for Novoheart. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Novoheart Neutral

Summary

BriaCell Therapeutics beats Novoheart on 5 of the 9 factors compared between the two stocks.

How does BriaCell Therapeutics compare to IntelGenx Technologies?

BriaCell Therapeutics (TSE:BCT) and IntelGenx Technologies (CVE:IGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

IntelGenx Technologies' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
IntelGenx Technologies N/A N/A N/A

BriaCell Therapeutics has higher earnings, but lower revenue than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
IntelGenx TechnologiesC$1.75M49.95-C$11.74M-C$0.08N/A

In the previous week, BriaCell Therapeutics had 1 more articles in the media than IntelGenx Technologies. MarketBeat recorded 1 mentions for BriaCell Therapeutics and 0 mentions for IntelGenx Technologies. BriaCell Therapeutics' average media sentiment score of 0.00 equaled IntelGenx Technologies'average media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
IntelGenx Technologies Neutral

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BriaCell Therapeutics beats IntelGenx Technologies on 5 of the 9 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export
MetricBriaCell TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$40.37MC$431.50MC$7.16BC$13.07B
Dividend Yield13.70%3.88%2.66%6.18%
P/E Ratio-5.423.0928.0236.51
Price / SalesN/A6,669.11540.3710.34
Price / CashN/A13.1349.2682.29
Price / Book1.4188.6710.964.52
Net Income-C$2.37M-C$96.07MC$3.57BC$299.09M
7 Day Performance4.60%0.17%2.12%1.85%
1 Month Performance5.57%2.10%5.25%1.71%
1 Year PerformanceN/A68.02%33.29%36.40%

BriaCell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$4.55
-1.9%		N/A-88.7%C$40.37MN/AN/A16
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
HBP
Helix BioPharma
N/AC$1.33
-5.7%		N/A+44.3%C$101.58MN/AN/A9
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel